Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-10-17 Sale | 2024-10-18 6:25 pm | Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director | 21,788 | $17.03 | $370,962 | 205,321 (Direct) | View |
| 2024-10-09 Sale | 2024-10-11 4:10 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 13,823 | $15.06 | $208,110 | 314,706 (Direct) | View |
| 2024-09-17 Sale | 2024-09-19 4:35 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 41,464 | $11.89 | $492,827 | 328,529 (Direct) | View |
| 2024-09-12 Sale | 2024-09-16 4:05 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 32,948 | $11.43 | $376,665 | 369,993 (Direct) | View |
| 2024-08-27 Sale | 2024-08-27 5:58 pm | Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer | 15,693 | $11.39 | $178,806 | 223,965 (Indirect Direct) | View |
| 2024-08-22 Sale | 2024-08-26 6:17 pm | Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer | 84,307 | $11.67 | $984,061 | 239,658 (Indirect Direct) | View |
| 2023-11-13 Purchase | 2023-11-15 6:55 pm | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 35,010 | $11.77 | $412,140 | 4,144,827 (Indirect Direct) | View |
| 2023-11-13 Purchase | 2023-11-15 6:54 pm | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT 10% Owner | 35,010 | $11.77 | $412,140 | 4,131,207 (Indirect) | View |
| 2023-11-08 Purchase | 2023-11-13 7:01 pm | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 140,605 | $10.98 | $1,543,563 | 4,109,817 (Indirect Direct) | View |
| 2023-11-08 Purchase | 2023-11-13 7:00 pm | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT 10% Owner | 140,605 | $10.98 | $1,543,563 | 4,096,197 (Indirect) | View |
| 2023-11-03 Purchase | 2023-11-07 7:00 pm | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 95,694 | $11.49 | $1,099,945 | 3,969,212 (Indirect Direct) | View |
| 2023-11-03 Purchase | 2023-11-07 6:59 pm | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT 10% Owner | 95,694 | $11.49 | $1,099,945 | 3,955,592 (Indirect) | View |
| 2023-09-28 Purchase | 2023-09-29 6:55 pm | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 76,511 | $13.68 | $1,046,848 | 3,873,518 (Indirect Direct) | View |
| 2023-09-28 Purchase | 2023-09-29 6:53 pm | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT 10% Owner | 76,511 | $13.68 | $1,046,848 | 3,859,898 (Indirect) | View |
| 2023-09-26 Purchase | 2023-09-27 8:19 pm | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 58,504 | $11.97 | $700,464 | 3,797,007 (Indirect Direct) | View |
| 2023-09-26 Purchase | 2023-09-27 8:18 pm | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT 10% Owner | 58,504 | $11.97 | $700,464 | 3,783,387 (Indirect) | View |
| 2023-09-22 Purchase | 2023-09-25 9:38 pm | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT 10% Owner | 100,740 | $11.19 | $1,127,064 | 3,724,883 (Indirect) | View |
| 2023-09-22 Purchase | 2023-09-25 9:37 pm | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 100,740 | $11.19 | $1,127,064 | 3,738,503 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-12-27 Gift | 2024-12-27 5:01 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | BERNS PAUL L Director | 133,097 | $0 | 7,818,166 (Direct) | View |
| 2024-10-17 Exercise | 2024-10-18 6:25 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director | 3,783 | $8.32 | 205,321 (Direct) | View |
| 2024-10-17 Exercise | 2024-10-18 6:25 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director | 10,000 | $2.52 | 205,321 (Direct) | View |
| 2024-10-17 Exercise | 2024-10-18 6:25 pm | N/A 2030-09-07 | Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director | 21,788 | $0 | 205,321 (Direct) | View |
| 2024-10-17 Exercise | 2024-10-18 6:25 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director | 8,005 | $8.79 | 205,321 (Direct) | View |
| 2024-09-12 Gift | 2024-09-13 5:22 pm | N/A 2031-09-20 | Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer | 606,970 | $0 | 836,700 (Direct) | View |
| 2024-04-17 Gift | 2024-06-28 9:00 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer | 238,965 | $0 | 323,965 (Indirect) | View |
| 2024-06-13 Option Award | 2024-06-14 4:18 pm | N/A 2034-06-12 | Neumora Therapeutics Inc. | NMRA | Ho Maykin Director | 48,671 | $0 | 48,671 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-14 4:16 pm | N/A 2034-06-12 | Neumora Therapeutics Inc. | NMRA | Piacquad David Director | 48,671 | $0 | 48,671 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-14 4:14 pm | N/A 2034-06-12 | Neumora Therapeutics Inc. | NMRA | Halawa Alaa Director | 48,671 | $0 | 48,671 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-14 4:13 pm | N/A 2034-06-12 | Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director | 48,671 | $0 | 48,671 (Direct) | View |
| 2024-06-13 Option Award | 2024-06-14 4:11 pm | N/A 2034-06-12 | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 48,671 | $0 | 32,008,426 (Direct) | View |
| 2024-04-22 Gift | 2024-04-24 5:00 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer | 114,703 | $0 | 212,203 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:21 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer | 255,000 | $0 | 493,965 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:20 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer | 292,500 | $0 | 407,203 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:19 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Suh Carol Y. Chief Operating Officer | 255,000 | $0 | 544,674 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:17 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | BERNS PAUL L Director | 513,750 | $0 | 8,160,666 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:15 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Gosebruch Henry O President & CEO | 240,000 | $0 | 764,793 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:14 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Milligan Michael Lee See Remarks | 61,875 | $0 | 65,698 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:13 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 150,000 | $0 | 502,941 (Direct) | View |
| 2023-12-08 Other | 2023-12-12 7:53 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT BYBEE CLINTON 10% Owner | 1,879,654 | $0 | 32,424,564 (Indirect) | View |
| 2023-12-08 Other | 2023-12-12 7:52 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners X LLC ARCH Venture Fund X L.P. ARCH Venture Partners X L.P. ARCH Venture Fund X Overage L.P. ARCH Venture Partners X Overage L.P. ARCH Venture Partners VII LLC ARCH Venture Partners VII L.P. ARCH Venture Fund VII L.P. ARCH Venture Partners VIII LLC ARCH Venture Fund VIII Overage L.P. 10% Owner | 1,879,654 | $0 | 32,424,564 (Indirect) | View |
| 2023-12-08 Other | 2023-12-12 7:52 pm | N/A N/A | Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner | 1,893,651 | $0 | 34,275,819 (Indirect) | View |
| 2023-12-11 Option Award | 2023-12-12 6:16 pm | N/A 2033-12-10 | Neumora Therapeutics Inc. | NMRA | Duncan Jason Chief Legal Officer | 400,000 | $0 | 400,000 (Direct) | View |
| 2023-09-19 Conversion | 2023-09-21 08:30 am | N/A N/A | Neumora Therapeutics Inc. | NMRA | FMR LLC See Remark 1 | 3,712,624 | $0 | 2,000,018 (Indirect) | View |